IN2012DN01216A - - Google Patents
Info
- Publication number
- IN2012DN01216A IN2012DN01216A IN1216DEN2012A IN2012DN01216A IN 2012DN01216 A IN2012DN01216 A IN 2012DN01216A IN 1216DEN2012 A IN1216DEN2012 A IN 1216DEN2012A IN 2012DN01216 A IN2012DN01216 A IN 2012DN01216A
- Authority
- IN
- India
- Prior art keywords
- cthyl
- imida
- phosphono
- humans
- vitro
- Prior art date
Links
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 abstract 1
- 238000012512 characterization method Methods 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Physiology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23022209P | 2009-07-31 | 2009-07-31 | |
| US28803609P | 2009-12-18 | 2009-12-18 | |
| US30211010P | 2010-02-06 | 2010-02-06 | |
| US31287910P | 2010-03-11 | 2010-03-11 | |
| US31850310P | 2010-03-29 | 2010-03-29 | |
| US35954410P | 2010-06-29 | 2010-06-29 | |
| PCT/US2010/043892 WO2011014766A2 (en) | 2009-07-31 | 2010-07-30 | Crystallization method and bioavailability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN01216A true IN2012DN01216A (cs) | 2015-04-10 |
Family
ID=43527595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1216DEN2012 IN2012DN01216A (cs) | 2009-07-31 | 2010-07-30 |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US8399023B2 (cs) |
| EP (2) | EP3295935B1 (cs) |
| JP (1) | JP5852569B2 (cs) |
| KR (1) | KR101813728B1 (cs) |
| CN (1) | CN102573809B (cs) |
| AU (2) | AU2010278860B2 (cs) |
| CA (1) | CA2769633C (cs) |
| CY (1) | CY1121952T1 (cs) |
| DK (1) | DK2459176T3 (cs) |
| ES (1) | ES2650665T3 (cs) |
| HR (1) | HRP20171755T1 (cs) |
| HU (1) | HUE034784T2 (cs) |
| IL (1) | IL217828B (cs) |
| IN (1) | IN2012DN01216A (cs) |
| LT (1) | LT2459176T (cs) |
| NO (1) | NO2459176T3 (cs) |
| PL (1) | PL2459176T3 (cs) |
| PT (1) | PT2459176T (cs) |
| SI (1) | SI2459176T1 (cs) |
| WO (1) | WO2011014766A2 (cs) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011014781A1 (en) * | 2009-07-31 | 2011-02-03 | Thar Pharmaceuticals, Inc. | Novel oral forms of a phosphonic acid derivative |
| US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| NO2459176T3 (cs) | 2009-07-31 | 2018-02-24 | ||
| HUE035744T2 (en) * | 2010-02-06 | 2018-05-28 | Gruenenthal Gmbh | Crystallization process and bioavailability |
| US9340565B2 (en) | 2010-11-24 | 2016-05-17 | Thar Pharmaceuticals, Inc. | Crystalline forms |
| US9999628B2 (en) | 2012-05-14 | 2018-06-19 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
| US8865757B1 (en) | 2014-05-28 | 2014-10-21 | Antecip Bioventures Ii Llp | Therapeutic compositions comprising imidazole and imidazolium compounds |
| US10016446B2 (en) | 2012-05-14 | 2018-07-10 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone |
| US11654152B2 (en) | 2012-05-14 | 2023-05-23 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
| US9770457B2 (en) | 2012-05-14 | 2017-09-26 | Antecip Bioventures Ii Llc | Neridronic acid for treating bone marrow lesion |
| US9289441B2 (en) | 2014-08-08 | 2016-03-22 | Antecip Bioventures Ii Llc | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
| US9827256B2 (en) | 2014-05-27 | 2017-11-28 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating lower back pain |
| US9861648B2 (en) | 2012-05-14 | 2018-01-09 | Antecip Boiventures Ii Llc | Osteoclast inhibitors for knee conditions |
| US9867839B2 (en) | 2012-05-14 | 2018-01-16 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for joint conditions |
| US9820999B2 (en) | 2012-05-14 | 2017-11-21 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
| US9662343B2 (en) | 2012-05-14 | 2017-05-30 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9844559B2 (en) | 2012-05-14 | 2017-12-19 | Antecip Bioventures Ii Llc | Neridronic acid for treating bone marrow lesions |
| US10350227B2 (en) | 2012-05-14 | 2019-07-16 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
| US9707245B2 (en) | 2012-05-14 | 2017-07-18 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
| US9655908B2 (en) | 2012-05-14 | 2017-05-23 | Antecip Bioventures Ii Llc | Neridronic acid molecular complex for treating complex regional pain syndrome |
| US9956237B2 (en) | 2012-05-14 | 2018-05-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
| US10034890B2 (en) | 2012-05-14 | 2018-07-31 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9717747B2 (en) | 2012-05-14 | 2017-08-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
| US9211257B2 (en) | 2012-05-14 | 2015-12-15 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
| US8802658B2 (en) * | 2012-05-14 | 2014-08-12 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
| US9956238B2 (en) | 2014-05-15 | 2018-05-01 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
| US9675626B2 (en) | 2012-05-14 | 2017-06-13 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9943531B2 (en) | 2014-08-08 | 2018-04-17 | Antecip Bioventures Ii Llc | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
| US10173986B2 (en) | 2012-05-14 | 2019-01-08 | Antecip Bioventures Ii Llc | Methods for the safe administration of imidazole or imidazolium compounds |
| US10493085B2 (en) | 2012-05-14 | 2019-12-03 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
| US9694023B2 (en) | 2012-05-14 | 2017-07-04 | Antecip Bioventures Ii Llc | Methods for the safe administration of imidazole or imidazolium compounds |
| US9789128B2 (en) | 2012-05-14 | 2017-10-17 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9867840B2 (en) | 2014-05-27 | 2018-01-16 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10111837B2 (en) | 2012-05-14 | 2018-10-30 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds |
| US9795622B2 (en) | 2012-05-14 | 2017-10-24 | Antecip Bioventures Ii Llc | Neridronic acid for treating pain associated with a joint |
| US9901589B2 (en) | 2012-05-14 | 2018-02-27 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9700570B2 (en) | 2014-05-27 | 2017-07-11 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10413561B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
| US10028969B2 (en) | 2012-05-14 | 2018-07-24 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10413560B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease |
| US10463682B2 (en) | 2012-05-14 | 2019-11-05 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating low back pain |
| US9956234B2 (en) | 2012-05-14 | 2018-05-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for joint conditions |
| US9895383B2 (en) | 2012-05-14 | 2018-02-20 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10028908B2 (en) | 2012-05-14 | 2018-07-24 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10004756B2 (en) | 2014-05-15 | 2018-06-26 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9707247B2 (en) | 2012-05-14 | 2017-07-18 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
| US20140349974A1 (en) * | 2014-08-12 | 2014-11-27 | Antecip Bioventures Ii Llc | Zoledronic acid dosage forms for the treatment of pain |
| US9925203B2 (en) | 2012-05-14 | 2018-03-27 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
| US9999629B2 (en) | 2012-05-14 | 2018-06-19 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10080765B2 (en) | 2012-05-14 | 2018-09-25 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
| US9669040B2 (en) | 2012-05-14 | 2017-06-06 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9827192B2 (en) | 2012-05-14 | 2017-11-28 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9949993B2 (en) | 2012-05-14 | 2018-04-24 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
| US10039773B2 (en) | 2012-05-14 | 2018-08-07 | Antecip Bioventures Ii Llc | Neridronic acid for treating arthritis |
| US10092581B2 (en) | 2014-05-15 | 2018-10-09 | Antecip Bioventures Ii Llc | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
| US9877977B2 (en) | 2012-05-14 | 2018-01-30 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9616078B2 (en) | 2012-05-14 | 2017-04-11 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease |
| US9427403B2 (en) * | 2012-05-14 | 2016-08-30 | Antecip Bioventures Ii Llc | Methods for the safe administration of imidazole or imidazolium compounds |
| US9782421B1 (en) | 2012-05-14 | 2017-10-10 | Antecip Bioventures Ii Llc | Neridronic acid molecular complex for treating complex regional pain syndrome |
| US10016445B2 (en) | 2012-05-14 | 2018-07-10 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| MX2016005396A (es) * | 2013-10-25 | 2017-03-01 | Antecip Bioventures Ii Llc | Composiciones para administracion oral de acido zoledronico o compuestos relacionados para tratar enfermedades. |
| US9079927B1 (en) | 2014-05-27 | 2015-07-14 | Antecip Bioventures Ii Llc | Substituted imidazolium compounds for treating disease |
| US9127069B1 (en) | 2014-06-11 | 2015-09-08 | Antecip Bioventures LLC | Compositions comprising rank/rankl antagonists and related compounds for treating pain |
| US9688765B2 (en) | 2014-06-11 | 2017-06-27 | Antecip Bioventures Ii Llc | Methods using RANK/RANKL antagonist antibodies for treating pain |
| WO2017049294A1 (en) * | 2015-09-18 | 2017-03-23 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
| CN112778365A (zh) * | 2020-12-30 | 2021-05-11 | 华南理工大学 | 一种唑来膦酸钙配合物及其制备方法 |
Family Cites Families (142)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3959361A (en) | 1970-03-20 | 1976-05-25 | Joh. A. Benckiser Gmbh | Process of producing amino methylene phosphonic acids |
| US3961934A (en) | 1974-12-19 | 1976-06-08 | Monsanto Company | Method for increasing the sucrose content of growing plants |
| DE3776880D1 (de) * | 1986-11-21 | 1992-04-02 | Ciba Geigy Ag | Neue substituierte alkandiphosphonsaeuren. |
| IE912115A1 (en) * | 1990-06-25 | 1992-01-01 | Takeda Chemical Industries Ltd | Bisphosphonic acid derivatives, their production and use |
| SK90093A3 (en) | 1991-02-26 | 1994-09-07 | Norwich Eaton Pharma | Mixture of phosphonite and estrogene for treatment of osteoporosis |
| US5431920A (en) | 1993-09-21 | 1995-07-11 | Merck Frosst, Canada, Inc. | Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents |
| CA2199252A1 (en) | 1994-09-09 | 1996-03-14 | Ann Dunbar Geddes | Methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone |
| US6541454B1 (en) * | 1995-04-04 | 2003-04-01 | Yissum Research Development Company Of The Hebrew University Jerusalem | Phosphonates, biphosphonates and pharmaceutical compositions containing them |
| GB9516268D0 (en) | 1995-08-08 | 1995-10-11 | Danbiosyst Uk | Compositiion for enhanced uptake of polar drugs from the colon |
| GB9710699D0 (en) | 1997-05-24 | 1997-07-16 | Danbiosyst Uk | Gastro-retentive controlled release system |
| ATE277606T1 (de) | 1997-06-11 | 2004-10-15 | Procter & Gamble | Filmüberzogene tablette für verbesserte verträglichkeit im oberen magen-darmtrakt |
| EP0998933A1 (de) | 1998-10-09 | 2000-05-10 | Boehringer Mannheim Gmbh | Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation |
| US8119159B2 (en) * | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
| AU2681300A (en) | 1999-02-22 | 2000-09-14 | Elan Corporation, Plc | Solid oral dosage form containing an enhancer |
| US7658938B2 (en) * | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
| SE9901272D0 (sv) | 1999-04-09 | 1999-04-09 | Astra Ab | New improved formulation |
| WO2000064516A1 (en) | 1999-04-22 | 2000-11-02 | Hydromed Sciences A Division Of Gp Strategies Corporation | Controlled delivery of bisphosphonates |
| IL146520A0 (en) * | 1999-05-21 | 2002-07-25 | Novartis Ag | Use of bisphosphonic acids for treating angiogenesis |
| AR021347A1 (es) * | 1999-10-20 | 2002-07-17 | Cipla Ltd | Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma |
| US6936275B2 (en) * | 1999-12-20 | 2005-08-30 | Scolr, Inc. | Amino acid modulated extended release dosage form |
| US6677320B2 (en) | 2000-01-20 | 2004-01-13 | Hoffmann-La Roches Inc. | Parenteral bisphosphonate composition with improved local tolerance |
| MXPA02009924A (es) * | 2000-04-07 | 2004-08-19 | Univ Texas | Composiones unicas de fosfolipidos de ion anfoterico y bisfosfonatos y uso de las composiciones como sistemas de suministro de bisfosfato con toxicidad gi reducida. |
| US6468559B1 (en) * | 2000-04-28 | 2002-10-22 | Lipocine, Inc. | Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods |
| KR100492110B1 (ko) * | 2000-05-05 | 2005-06-02 | 에프. 호프만-라 로슈 아게 | 비스포스폰산 또는 그의 염을 포함하는 피하 투여용겔-유사 약학 조성물 |
| RU2288722C2 (ru) | 2000-06-20 | 2006-12-10 | Новартис Аг | Способ введения бисфосфонатов |
| US8052987B2 (en) | 2000-06-20 | 2011-11-08 | Novartis Pharmaceuticals Corporation | Method of administering bisphosphonates |
| US6476006B2 (en) * | 2000-06-23 | 2002-11-05 | Teva Pharmaceutical Industries, Ltd. | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates |
| US7008640B2 (en) * | 2000-07-17 | 2006-03-07 | Yamanouchi Pharmaceutical Co., Ltd. | Pharmaceutical composition for oral use with improved absorption |
| AU2002221339B2 (en) * | 2001-02-06 | 2006-04-27 | The Sydney Children's Hospitals Network (Randwick And Westmead) (Incorporating The Royal Alexandra Hospital For Children) | A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis |
| CN1492763B (zh) * | 2001-03-01 | 2012-05-23 | 艾米斯菲尔技术有限公司 | 用于递送二膦酸盐的组合物 |
| AU2002244520B2 (en) | 2001-04-03 | 2007-05-24 | The Royal Alexandra Hospital For Children | A drug for use in bone grafting |
| PL366836A1 (en) | 2001-04-30 | 2005-02-07 | Novologix Gmbh | Antibacterial agent |
| WO2002089816A1 (en) | 2001-05-02 | 2002-11-14 | Novartis Ag | Method of administration of bisphosphonates by inhalation in the treatment or prevention of bone resorption and osteoporosis |
| CN1277545C (zh) * | 2001-05-02 | 2006-10-04 | 诺瓦提斯公司 | 二膦酸类化合物在制备用于治疗与前列腺癌有关的骨转移瘤的药物中的用途 |
| WO2002092069A1 (en) * | 2001-05-11 | 2002-11-21 | Elan Corporation, Plc | Permeation enhancers |
| CA2454200A1 (en) | 2001-07-17 | 2003-01-30 | Teva Pharmaceutical Industries Ltd. | Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate |
| ATE382347T1 (de) * | 2001-10-19 | 2008-01-15 | Novartis Pharma Gmbh | Pharmazeutische zusammensetzung zur verwendung bei der behandlung von malignen erkrankungen, umfassend eine kombination aus bisphosphonaten, einem cox-2 inhibitor und einem taxol |
| EP1458400A1 (en) | 2001-12-13 | 2004-09-22 | Merck & Co., Inc. | Liquid bisphosphonate formulations for bone disorders |
| ITMI20020908A1 (it) * | 2002-04-29 | 2003-10-29 | Chemi Spa | Processo di preparazione di sodio alendronato |
| CA2763775C (en) * | 2002-05-10 | 2014-01-07 | F. Hoffmann-La Roche Ag | Bisphosphonic acids for the treatment and prevention of osteoporosis |
| ATE461205T1 (de) * | 2002-05-17 | 2010-04-15 | Teva Pharma | Verwendung von bestimmten lösungsmitteln zur herstellung von bisphosphonsäuren |
| US20040047835A1 (en) * | 2002-09-06 | 2004-03-11 | Cell Therapeutics, Inc. | Combinatorial drug therapy using polymer drug conjugates |
| GB0220885D0 (en) | 2002-09-09 | 2002-10-16 | Novartis Ag | Organic compounds |
| US20040138180A1 (en) * | 2002-10-03 | 2004-07-15 | Barr Laboratories, Inc. | Bisphosphonate composition and process for the preparation thereof |
| CN1705485A (zh) | 2002-10-15 | 2005-12-07 | 诺瓦提斯公司 | 施用双膦酸类化合物的方法 |
| NZ536273A (en) | 2002-12-20 | 2007-08-31 | Hoffmann La Roche | High dose ibandronate formulation |
| EP1525207A2 (en) * | 2003-02-27 | 2005-04-27 | Teva Pharmaceutical Industries Limited | Process for purification of zoledronic acid |
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| CA2513746C (en) | 2003-02-28 | 2012-08-28 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| US20040220264A1 (en) * | 2003-03-17 | 2004-11-04 | Yu Ruey J | Bioavailability and improved delivery of acidic pharmaceutical drugs |
| GB0310919D0 (en) | 2003-05-13 | 2003-06-18 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
| TW200510394A (en) | 2003-05-29 | 2005-03-16 | Synta Pharmaceuticals Corp | Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss |
| EP1640010A1 (en) * | 2003-07-01 | 2006-03-29 | Astellas Pharma Inc. | Agent inducing increase in bone mass |
| ES2322592T3 (es) | 2003-07-03 | 2009-06-23 | Teva Pharmaceutical Industries Ltd. | Formas cristalinas de acido zoledronico, formas cristlinas de la sal sodica de zoledronato, sal sodica de zoledronato amorfa y procedimientos para su preparacion. |
| EP1656386B1 (en) * | 2003-08-21 | 2009-12-09 | Sun Pharmaceuticals Industries Ltd. | A process for preparation of bisphosphonic acid compounds |
| MY141763A (en) | 2003-09-18 | 2010-06-30 | Novartis Ag | Pharmaceutical products comprising bisphosphonates |
| US20050119230A1 (en) * | 2003-09-18 | 2005-06-02 | Alexandra Glausch | Pharmaceutical products comprising bisphosphonated |
| AU2004273672A1 (en) * | 2003-09-19 | 2005-03-31 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a bisphosphonate |
| WO2005048979A2 (en) | 2003-10-06 | 2005-06-02 | Torrent Pharmaceuticals Limited | Pharmaceutical composition having casing with multiple micro tablets |
| WO2005037157A1 (en) | 2003-10-14 | 2005-04-28 | Dermatrends, Inc. | Enhancing transdermal administration of hydrophilic drugs |
| AR046773A1 (es) * | 2003-12-23 | 2005-12-21 | Novartis Ag | Formulaciones farmaceuticas de bisfosfonatos |
| WO2005063717A1 (en) | 2003-12-26 | 2005-07-14 | Natco Pharma Limited | An improved process for the preparation of zoledronic acid |
| WO2005099676A2 (en) | 2004-04-07 | 2005-10-27 | Dermatrends, Inc. | Transdermal delivery system for use with basic permeation enhancers |
| US20080286359A1 (en) * | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
| US7645460B2 (en) * | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of risedronate |
| US20080287400A1 (en) * | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
| KR20070015596A (ko) | 2004-05-24 | 2007-02-05 | 더 프록터 앤드 갬블 캄파니 | 킬레이팅제를 함유하는 비스포스포네이트의 고형의 장용경구 투여 형태 |
| AU2011218625B2 (en) | 2004-05-24 | 2014-03-20 | Theramex HQ UK Limited | Dosage forms of risedronate |
| US7645459B2 (en) * | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
| US20050289182A1 (en) | 2004-06-15 | 2005-12-29 | Sand Hill Systems Inc. | Document management system with enhanced intelligent document recognition capabilities |
| WO2006019843A1 (en) | 2004-07-15 | 2006-02-23 | Nanobac Life Sciences | Methods and compositions for the administration of calcium chelators, bisphosphonates and/or citrate compounds and their pharmaceutical uses |
| WO2006020009A1 (en) | 2004-07-23 | 2006-02-23 | The Procter & Gamble Company | Solid oral dosage form of a bisphosphonate containing a chelating agent |
| EP1781258A1 (en) | 2004-08-20 | 2007-05-09 | Mepha AG | Formulations of bisphosphonates |
| US20060068010A1 (en) | 2004-09-30 | 2006-03-30 | Stephen Turner | Method for improving the bioavailability of orally delivered therapeutics |
| US20060134190A1 (en) | 2004-12-16 | 2006-06-22 | Banner Pharmacaps Inc. | Formulations of bisphosphonate drugs with improved bioavailability |
| US20060178439A1 (en) | 2005-01-04 | 2006-08-10 | Mohakhud Pradeep K | Crystalline form of zoledronic acid |
| KR100815040B1 (ko) | 2005-01-31 | 2008-03-18 | 주식회사종근당 | 비스포스포네이트계 약물의 경구흡수 개선을 위한약제학적 조성물 |
| EP1865935B1 (en) * | 2005-02-17 | 2011-06-08 | Hadasit Medical Research Services and Development Ltd. | Bisphosphonates for treating endometriosis |
| WO2006102117A1 (en) * | 2005-03-17 | 2006-09-28 | Elan Pharma International Limited | Nanoparticulate biphosphonate compositions |
| EP1883644A2 (en) | 2005-05-06 | 2008-02-06 | Medichem, S.A. | Process of making geminal bisphosphonic acids and pharmaceutically acceptable salts and/or hydrates thereof |
| US20070014319A1 (en) | 2005-07-15 | 2007-01-18 | Zetetic Institute | Continuously Tunable External Cavity Diode Laser Sources With High Tuning And Switching Rates And Extended Tuning Ranges |
| AR054673A1 (es) | 2005-07-28 | 2007-07-11 | Gador Sa | Una forma cristalina del acido zoledronico, un proceso para su obtencion y la composicion farmaceutica que la comprende |
| US20070049557A1 (en) * | 2005-08-24 | 2007-03-01 | Hashim Ahmed | Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers |
| KR20080042131A (ko) | 2005-09-12 | 2008-05-14 | 닥터 레디스 레보러터리즈 리미티드 | 졸레드론산의 결정성 삼수화물 |
| JO3006B1 (ar) | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
| US7473684B2 (en) * | 2005-09-16 | 2009-01-06 | Selamine Limited | Bisphosphonate formulation |
| US20070088161A1 (en) * | 2005-10-19 | 2007-04-19 | Stockel Richard F | Novel chelated bisphosphonates for use as pharmaceutical agents |
| WO2007069049A2 (en) | 2005-12-16 | 2007-06-21 | Wockhardt Ltd | Processes for the preparation of pure zoledronic acid |
| WO2007083240A2 (en) * | 2006-01-20 | 2007-07-26 | Aurobindo Pharma Limited | An improved process for the preparation of bisphosphonic acids |
| JP2009525976A (ja) * | 2006-02-06 | 2009-07-16 | サイプレス バイオサイエンス， インコーポレイテッド | ビスホスホネート及び葉酸代謝拮抗剤を含む組成物 |
| WO2007096896A1 (en) * | 2006-02-20 | 2007-08-30 | Alembic Limited | An improved process for the preparation of biphosphonic derivatives |
| US20090137808A1 (en) * | 2006-03-21 | 2009-05-28 | Albemarle Corporation | Process for manufacturing bisphosphonic acids |
| BRPI0710503A2 (pt) * | 2006-04-07 | 2011-08-16 | Merrion Res Iii Ltd | uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral |
| WO2007124274A1 (en) * | 2006-04-21 | 2007-11-01 | The Uab Research Foundation | Treating neoplasms |
| WO2007125521A2 (en) | 2006-05-02 | 2007-11-08 | Ranbaxy Laboratories Limited | Polymorphic form of zoledronic acid and processes for their preparation |
| EP2040731A4 (en) | 2006-06-09 | 2010-05-19 | Merrion Res Iii Ltd | SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR |
| AR063121A1 (es) | 2006-10-05 | 2008-12-30 | Novartis Ag | Composicion farmaceutica |
| EP1923394A1 (en) | 2006-11-16 | 2008-05-21 | Sandoz A/S | Reagent and use thereof for the production of bisphosphonates |
| CA2669489A1 (en) * | 2006-11-17 | 2008-05-22 | Besins Healthcare | Liquid pharmaceutical compositions comprising a bisphosphonate compound |
| EP1925621A1 (en) * | 2006-11-27 | 2008-05-28 | Novartis AG | Crystalline forms of zoledronic acid |
| US20080139514A1 (en) * | 2006-11-29 | 2008-06-12 | Subhash Pandurang Gore | Diphosphonic acid pharmaceutical compositions |
| KR100775440B1 (ko) * | 2006-12-20 | 2007-11-12 | 동우신테크 주식회사 | 리세드로네이트 나트륨 헤미펜타히드레이트의 제조방법 |
| US8974801B2 (en) | 2006-12-21 | 2015-03-10 | Amphastar Pharmaceuticals Inc. | Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate |
| TW200843802A (en) | 2007-02-09 | 2008-11-16 | Drugtech Corp | Compositions for improving gastrointestinal nutrient and drug absorption |
| CA2677670C (en) | 2007-03-20 | 2010-08-03 | Centre De Recherche Sur Les Biotechnologies Marines | Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof |
| US20090023683A1 (en) * | 2007-07-16 | 2009-01-22 | Chandrasekhar Kocherlakota | Complexes comprising zoledronic acid and cyclodextrins |
| WO2009018834A1 (en) | 2007-08-06 | 2009-02-12 | Pharmathen S.A. | Pharmaceutical composition containing bisphosphonate and method for the preparation thereof |
| KR101165455B1 (ko) | 2007-09-10 | 2012-07-12 | 한스바이오메드 주식회사 | 인산칼슘 마이크로스피어 약물전달체 및 이의 제조방법 |
| WO2009042179A1 (en) | 2007-09-24 | 2009-04-02 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of ibandronic acid and processeses for the preparation thereof |
| US20090082312A1 (en) * | 2007-09-25 | 2009-03-26 | Protia, Llc | Deuterium-enriched zoledronic acid |
| AU2008303129B2 (en) | 2007-09-25 | 2013-08-01 | Formulex Pharma Innovations Ltd. | Compositions comprising lipophilic active compounds and method for their preparation |
| ITPA20070034A1 (it) | 2007-10-30 | 2009-04-30 | Tetrapharm S R L | Bifosfonati geminali, loro preparazione e loro impiego in campo oncologico. |
| WO2009067766A1 (en) * | 2007-11-26 | 2009-06-04 | Seeker Wireless Pty Limited | Methods and systems for zone creation and adaption |
| AU2008328797B2 (en) | 2007-11-30 | 2011-11-03 | Novartis Ag | C2-C5-Alkyl-imidazole-bisphosphonates |
| WO2009072119A2 (en) | 2007-12-04 | 2009-06-11 | Ben-Gurion University Of The Negev Research And Development Authority | Amphiphilic peptide matrices for treatment of osteoporosis |
| EP2255199A1 (en) * | 2008-02-19 | 2010-12-01 | Jovesis Inc. | Microparticle compositions to modify cancer promoting cells |
| WO2009107850A2 (en) | 2008-02-26 | 2009-09-03 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivative and use thereof |
| FR2928270B1 (fr) | 2008-03-10 | 2011-01-21 | Erytech Pharma | Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os |
| EP2273980A2 (en) | 2008-04-04 | 2011-01-19 | Novartis AG | Pharmaceutical composition with bisphosphonate |
| JP2009302891A (ja) | 2008-06-13 | 2009-12-24 | Sony Corp | 情報処理装置 |
| WO2010014766A1 (en) | 2008-07-31 | 2010-02-04 | Warner Chilcott Company, Llc | Low dosage forms of risedronate or its salts |
| US8008329B2 (en) * | 2008-08-01 | 2011-08-30 | Dong Wha Pharmaceutical Co., Ltd. | Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmacuetical composition comprising benzamidine derivative or it's salt, and bisphosphonate |
| WO2010060619A1 (en) | 2008-11-26 | 2010-06-03 | Synthon B.V. | Process for making zoledronic acid |
| US20100158905A1 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Combination therapy of arthritis with tranilast |
| EP2400851A4 (en) | 2009-02-25 | 2012-09-05 | Merrion Res Iii Ltd | COMPOSITION AND ACTIVE COMPOSITION OF BISPHOSPHONATES |
| US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| WO2011014781A1 (en) * | 2009-07-31 | 2011-02-03 | Thar Pharmaceuticals, Inc. | Novel oral forms of a phosphonic acid derivative |
| NO2459176T3 (cs) | 2009-07-31 | 2018-02-24 | ||
| US20110182985A1 (en) | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
| HUE035744T2 (en) | 2010-02-06 | 2018-05-28 | Gruenenthal Gmbh | Crystallization process and bioavailability |
| WO2011132826A1 (en) | 2010-04-19 | 2011-10-27 | Snu R&Db Foundation | Transdermal drug delivery system and pharmaceutical composition for preventing or treating bone diseases |
| US8946199B2 (en) * | 2010-04-26 | 2015-02-03 | Ketan Desai | Co-administration of steroids and Zoledronic acid to prevent and treat side effects from Zoledronic acid infusion |
| US9340565B2 (en) | 2010-11-24 | 2016-05-17 | Thar Pharmaceuticals, Inc. | Crystalline forms |
| CN102070668B (zh) | 2010-12-23 | 2013-07-24 | 蚌埠丰原医药科技发展有限公司 | 一种利用相转移催化剂制备唑来膦酸及其钠盐的方法 |
| US8993057B2 (en) | 2011-10-22 | 2015-03-31 | Masoud Salavati-Niasari | Method for preparing silica-dysprosium oxide core-shell nanoparticles |
| JP2015518828A (ja) | 2012-05-14 | 2015-07-06 | アンテシップ バイオベンチャーズ トゥー エルエルシー | 炎症性疼痛および関連症状を緩和するためのゾレドロン酸または関連化合物を含む組成物 |
| US20140349974A1 (en) | 2014-08-12 | 2014-11-27 | Antecip Bioventures Ii Llc | Zoledronic acid dosage forms for the treatment of pain |
| CN103070668A (zh) | 2013-01-02 | 2013-05-01 | 北京工业大学 | 心脏年龄检测仪及其检测方法 |
| EP3052104B1 (en) | 2013-10-04 | 2020-12-02 | The Regents of The University of California | Treating inflammation using llp2a-bisphosphonate conjugates and mesenchymal stem cells |
| WO2017049294A1 (en) | 2015-09-18 | 2017-03-23 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
-
2010
- 2010-07-30 NO NO10805109A patent/NO2459176T3/no unknown
- 2010-07-30 HU HUE10805109A patent/HUE034784T2/en unknown
- 2010-07-30 SI SI201031592T patent/SI2459176T1/en unknown
- 2010-07-30 PL PL10805109T patent/PL2459176T3/pl unknown
- 2010-07-30 IN IN1216DEN2012 patent/IN2012DN01216A/en unknown
- 2010-07-30 JP JP2012523084A patent/JP5852569B2/ja not_active Expired - Fee Related
- 2010-07-30 DK DK10805109.5T patent/DK2459176T3/en active
- 2010-07-30 LT LTEP10805109.5T patent/LT2459176T/lt unknown
- 2010-07-30 ES ES10805109.5T patent/ES2650665T3/es active Active
- 2010-07-30 EP EP17180990.8A patent/EP3295935B1/en active Active
- 2010-07-30 WO PCT/US2010/043892 patent/WO2011014766A2/en not_active Ceased
- 2010-07-30 AU AU2010278860A patent/AU2010278860B2/en not_active Ceased
- 2010-07-30 HR HRP20171755TT patent/HRP20171755T1/hr unknown
- 2010-07-30 CN CN201080043099.3A patent/CN102573809B/zh not_active Expired - Fee Related
- 2010-07-30 KR KR1020127005170A patent/KR101813728B1/ko not_active Expired - Fee Related
- 2010-07-30 EP EP10805109.5A patent/EP2459176B1/en active Active
- 2010-07-30 CA CA2769633A patent/CA2769633C/en not_active Expired - Fee Related
- 2010-07-30 US US12/847,568 patent/US8399023B2/en not_active Expired - Fee Related
- 2010-07-30 PT PT108051095T patent/PT2459176T/pt unknown
-
2012
- 2012-01-30 IL IL217828A patent/IL217828B/en not_active IP Right Cessation
-
2013
- 2013-02-13 US US13/766,034 patent/US8933057B2/en not_active Expired - Fee Related
- 2013-03-14 US US13/826,691 patent/US9334296B2/en not_active Expired - Fee Related
-
2016
- 2016-04-19 US US15/132,707 patent/US20170022226A1/en not_active Abandoned
- 2016-08-25 AU AU2016219654A patent/AU2016219654B2/en not_active Ceased
-
2017
- 2017-11-21 US US15/819,191 patent/US10323052B2/en not_active Expired - Fee Related
- 2017-11-28 CY CY20171101247T patent/CY1121952T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN01216A (cs) | ||
| AU2016219653A1 (en) | Crystallization Method and Bioavailability | |
| MY156383A (en) | Pharmaceutical compositions | |
| TN2012000126A1 (en) | Polycyclic compounds as lysophosphatidic acid receptor antagonists | |
| PH12013501136A1 (en) | Lysophosphatidic acid receptor antagonists and uses thereof | |
| MX2013001677A (es) | Formulaciones estables de linaclotida. | |
| MX2012007806A (es) | Composiciones farmaceuticas para administracion oral de peptidos de insulina. | |
| WO2011041729A3 (en) | Compounds as lysophosphatidic acid receptor antagonists | |
| WO2011017350A3 (en) | Compounds as lysophosphatidic acid receptor antagonists | |
| MX2018002627A (es) | Metodo de cristalizacion y biodisponibilidad. | |
| MY189427A (en) | Pyrazolyl quinoxaline kinase inhibitors | |
| MY163055A (en) | Polycyclic antagonists of lysophosphatidic acid receptors | |
| PH12012502452A1 (en) | Vectors and sequences for the treatment of diseases | |
| MX2019012939A (es) | Formulaciones que contienen linaclotida para administracion oral. | |
| MX347734B (es) | Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas. | |
| EP2488210A4 (en) | METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION USING IN VITO OR IN VITRO-ADMINISTERED OLIGONUCLEOTIDE MEDICAMENTS | |
| MX2010008852A (es) | Formulaciones de flibanserina. | |
| IL213671A (en) | Pharmaceutical preparations containing alglitazar, a process for their preparation and use for the preparation of medicines | |
| MX341642B (es) | Composicion de liberacion sostenida que contiene peptidos como ingredientes activos. | |
| TN2011000617A1 (en) | 17 - alkyl-17 -oxy-oestratrienes | |
| EP2563785A4 (en) | Compounds as Agonists Against S1P1 Receptors | |
| MY148088A (en) | Stable nanoparticle formulations | |
| ZA201005951B (en) | Controlled release drug delivery systems and pharmaceutical compositions formed therewith |